JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

MLA

Kani, Kian, et al. “JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-Mutant NSCLC Cell Lines.” Molecular Cancer Therapeutics, vol. 16, no. 8, Aug. 2017, pp. 1645–57. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-16-0564.

APA

Kani, K., Garri, C., Tiemann, K., Malihi, P. D., Punj, V., Nguyen, A. L., Lee, J., Hughes, L. D., Alvarez, R. M., Wood, D. M., Joo, A. Y., Katz, J. E., Agus, D. B., & Mallick, P. (2017). JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 16(8), 1645–1657. https://doi.org/10.1158/1535-7163.MCT-16-0564

Chicago

Kani, Kian, Carolina Garri, Katrin Tiemann, Paymaneh D Malihi, Vasu Punj, Anthony L Nguyen, Janet Lee, et al. 2017. “JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-Mutant NSCLC Cell Lines.” Molecular Cancer Therapeutics 16 (8): 1645–57. doi:10.1158/1535-7163.MCT-16-0564.